GLP-1 Drugs Linked to Lower Colon Cancer Death Rates in Obese Patients
A recent UC San Diego study suggests that glucagon-like peptide-1 (GLP-1) receptor agonists may significantly improve outcomes for colon cancer patients. Researchers analyzed data from over 6,800 patients, finding those taking GLP-1 medications had less than half the five-year mortality rate compared to those not on the drugs. This protective effect remained even after accounting for various health factors, with a more pronounced benefit in patients with high BMIs. While the exact mechanisms are still under investigation, the results point to potential anti-cancer benefits beyond the drugs’ known effects on blood sugar, inflammation, and weight.
John Q. Hosedrinker